Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14718)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 28, 2021 (publication date) through Apr 10, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021; 27(32): 5376-5391 [PMID: 34539139 DOI: 10.3748/wjg.v27.i32.5376] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i32/5376.htm |
| Number | Citing Articles |
| 1 |
Meijun Yue, Chunyu Li, Guohui Li. New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury. International Immunopharmacology 2024; 131: 111799 doi: 10.1016/j.intimp.2024.111799
|
| 2 |
Yoshihiro Ikura, Takako Okubo, Yasuhiro Sakai. Liver biopsy in the post-hepatitis C virus era in Japan. World Journal of Gastroenterology 2024; 30(14): 1949-1957 doi: 10.3748/wjg.v30.i14.1949
|
| 3 |
Nikola Nikolajevic, Milan Nikolajevic, Ivana Pantic, Bojan Korica, Magdalena Kotseva, Tamara Alempijevic, Dorde Jevtic, Cristian I Madrid, Igor Dumic. Drug-Induced Liver Injury Due to Doxycycline: A Case Report and Review of Literature. Cureus 2024; doi: 10.7759/cureus.59687
|
| 4 |
Zengfu Zhang, Xu Liu, Dawei Chen, Jinming Yu. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01102-y
|
| 5 |
J.A. Velarde-Ruiz Velasco, D.K. Tapia Calderón, S. Cerpa-Cruz, J.A. Velarde-Chávez, J.F. Uribe Martínez, E.S. García Jiménez, J.M. Aldana Ledesma, Á. Díaz-González, J. Crespo. Hepatitis inmunomediada: conceptos básicos y tratamiento. Revista de Gastroenterología de México 2024; 89(1): 106 doi: 10.1016/j.rgmx.2023.12.003
|
| 6 |
Zunirah Ahmed, Sunyoung Lee, David Victor 3rd, Sudha Kodali. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 1911 doi: 10.2147/JHC.S395080
|
| 7 |
Hui Yang, Zhexin Ding, Zhuoling An, Yong Zhao, Hezhe Lu. Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study. Expert Opinion on Drug Safety 2024; : 1 doi: 10.1080/14740338.2024.2343023
|
| 8 |
C. Leyh, C. Roderburg, T. Lüdde. Erkennen und Behandeln von Nebenwirkungen der Immuntherapie. Die Gastroenterologie 2025; doi: 10.1007/s11377-025-00894-z
|
| 9 |
Understanding and using Animal Models of Hepatotoxicity. Current Pharmaceutical Design 2025; 31(12): 943 doi: 10.2174/0113816128338726241029175250
|
| 10 |
Kefan Chen, Junhao He, Jing Xu, Jie Chen. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1088741
|
| 11 |
Tasneem Abaza, Mostafa K. Abd El-Aziz, Kerolos Ashraf Daniel, Paraskevi Karousi, Maria Papatsirou, Sherif Ashraf Fahmy, Nadia M. Hamdy, Christos K. Kontos, Rana A. Youness. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy. International Journal of Molecular Sciences 2023; 24(22): 16484 doi: 10.3390/ijms242216484
|
| 12 |
Qimeng Gao, Imran J. Anwar, Nader Abraham, Andrew S. Barbas. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers 2021; 13(24): 6307 doi: 10.3390/cancers13246307
|
| 13 |
H M M T B Herath, Nadiene G Lutchman, May Saleh, Leena Naidu, Shyama Balasuriya Alagoda, Stefen Brady, Sunil Wimalaratna. Neurological manifestations in malignant melanoma. Practical Neurology 2024; 24(5): 428 doi: 10.1136/pn-2023-003966
|
| 14 |
Alexandra Shingina, Nizar Mukhtar, Jamilé Wakim-Fleming, Saleh Alqahtani, Robert J. Wong, Berkeley N. Limketkai, Anne M. Larson, Lafaine Grant. Acute Liver Failure Guidelines. American Journal of Gastroenterology 2023; 118(7): 1128 doi: 10.14309/ajg.0000000000002340
|
| 15 |
Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari. What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?. Expert Opinion on Drug Metabolism & Toxicology 2024; 20(1-2): 5 doi: 10.1080/17425255.2024.2314059
|
| 16 |
Lixia Liang, Yan Li, Yansui Hong, Tianxing Ji, Hao Chen, Zhifang Lin. Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy. Current Oncology 2023; 30(8): 7189 doi: 10.3390/curroncol30080521
|
| 17 |
Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lian Li, Lan Bai, Yuan Bian. Immune-related adverse events of immune checkpoint inhibitors: a review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1167975
|
| 18 |
Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, Enrica Teresa Tanda, Lara Vera, Mara Boschetti, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Federico Gatto. Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1550702
|
| 19 |
Ji Hyeon Park, Jung Hyun Kim, Eun Young Jeon, Hu Kyoung Lee, Myung Sook Min. Analysis of Hepatic Adverse Event in Patients Treated with Immune Checkpoint Inhibitor. Journal of Korean Society of Health-System Pharmacists 2022; 39(4): 476 doi: 10.32429/jkshp.2022.39.4.004
|
| 20 |
Xiayang Ren, Lu Li, Yiran Chen, Xiangli Cui, Rui Wan, Yanfeng Wang. Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12947-7
|
| 21 |
Matteo Rosellini, Elisa Tassinari, Andrea Marchetti, Valentina Tateo, Giacomo Nuvola, Alessandro Rizzo, Francesco Massari, Veronica Mollica. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma. Expert Opinion on Drug Safety 2023; 22(4): 279 doi: 10.1080/14740338.2023.2203486
|
| 22 |
Laine Lyles, Reagan Farmer, Marwan Abougergi. A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis. ACG Case Reports Journal 2023; 10(9): e01162 doi: 10.14309/crj.0000000000001162
|
| 23 |
Yee Hui Yeo, Walid Ayoub, Ju Dong Yang, Alexander Kuo, Hirsh D. Trivedi. Beyond the Checkpoint: Severe Axitinib-induced Liver Injury. ACG Case Reports Journal 2023; 10(11): e01177 doi: 10.14309/crj.0000000000001177
|
| 24 |
Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valeriy V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Alexander E. Kuzminov, Evgeny V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergey V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Ksenia A. Sarantseva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tyurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Marina V. Chernykh, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Marina M. Khulamkhanova. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology 2022; 24(3): 269 doi: 10.26442/18151434.2022.3.201848
|
| 25 |
Yukinori Endo, Katie L. Winarski, Md Sanaullah Sajib, Anna Ju, Wen Jin Wu. Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. International Journal of Molecular Sciences 2023; 24(14): 11694 doi: 10.3390/ijms241411694
|
| 26 |
Thomas M. Ruli, Ethan D. Pollack, Atul Lodh, Charles D. Evers, Christopher A. Price, Mohamed Shoreibah. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review. Cancers 2024; 16(11): 2042 doi: 10.3390/cancers16112042
|
| 27 |
Essam Al Ageeli, Jawaher A. Abdulhakim, Mohammad H. Hussein, Maryam M. Alnoman, Samia S. Alkhalil, Peter P. Issa, Nader A. Nemr, Ahmed Abdelmaksoud, Dhaifallah A. Alenizi, Manal S. Fawzy, Eman A. Toraih. The HCV-Melanoma Paradox: First Multi-Cohort and Molecular Net-Work Analysis Reveals Lower Incidence but Worse Outcomes—Integrating Clinical, Real-World, and In Silico Data. Medicina 2024; 60(9): 1531 doi: 10.3390/medicina60091531
|
| 28 |
Soon Kyu Lee, Jong Young Choi, Eun Sun Jung, Jung Hyun Kwon, Jeong Won Jang, Si Hyun Bae, Seung Kew Yoon. An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences 2023; 24(5): 5002 doi: 10.3390/ijms24055002
|
| 29 |
Lucia Parlati, Mehdi Sakka, Aurelia Retbi, Samir Bouam, Lamia Hassani, Jean-François Meritet, Pierre Rufat, Dominique Bonnefont-Rousselot, Rui Batista, Benoit Terris, Agnès Bellanger, Dominique Thabut, Aurore Vozy, Jean-Philippe Spano, Romain Coriat, François Goldwasser, Selim Aractingi, Philippe Sogni, Stanislas Pol, Vincent Mallet, Jérôme Alexandre, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Sixtine De Percin, Nora Kramkimel, Olivier Huillard, Jeanne Chapron, Benedicte Deau-Fischer, Marie-Laure Brandely-Piat, Diane Damotte, Audrey Lupo, Marco Alifano, Marion Corouge, Clémence Hollande, Hélène Fontaine, Lorianne Lair Mehiri, Anaïs Vallet Pichard, Patrick Tilleul. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors. JHEP Reports 2023; 5(12): 100880 doi: 10.1016/j.jhepr.2023.100880
|
| 30 |
Hao Chi Zhang, Lan Sun Wang, Ethan Miller. Managing Immunotherapy Related Organ Toxicities. 2022; : 119 doi: 10.1007/978-3-031-00241-0_7
|
| 31 |
Kevin Mok, Claudia Wu, Stephen Chan, Grace Wong, Vincent Wai-Sun Wong, Brigette Ma, Rashid Lui. Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors. Clinical Colorectal Cancer 2024; 23(1): 4 doi: 10.1016/j.clcc.2023.12.003
|
| 32 |
J.A. Velarde-Ruiz Velasco, D.K. Tapia Calderón, S. Cerpa-Cruz, J.A. Velarde-Chávez, J.F. Uribe Martínez, E.S. García Jiménez, J.M. Aldana Ledesma, Á. Díaz-González, J. Crespo. Immune-mediated hepatitis: Basic concepts and treatment. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 106 doi: 10.1016/j.rgmxen.2023.12.001
|
| 33 |
Nabanita Mukherjee, Elizabeth Katsnelson, Tonya M. Brunetti, Kylie Michel, Kasey L. Couts, Karoline A. Lambert, William A. Robinson, Martin D. McCarter, David A. Norris, Richard P. Tobin, Yiqun G. Shellman. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death & Disease 2024; 15(3) doi: 10.1038/s41419-024-06524-w
|
| 34 |
Tatsuya Furuno, Rintaro Sogawa, Takanori Hashimoto, Shunsuke Matsuo, Wakako Shirahama, Tomoko Kamura, Kazuhisa Hosoya, Yoko Senjyu, Yoshio Yamashita, Takuya Inoue, Moriyasu Yamauchi, Hiroo Katsuya, Mitsuru Noguchi, Naoko Sueoka-Aragane, Chisato Shimanoe. Association between the Prognostic Nutritional Index and the Occurrence of Immune-Related Adverse Events. Biological and Pharmaceutical Bulletin 2024; 47(2): 361 doi: 10.1248/bpb.b23-00760
|
| 35 |
Christine Podesta, Mahaz Kayani, Rebecca Goody, Adel Samson. Combination treatment of HCC with SBRT and immune checkpoint inhibition. Critical Reviews in Oncology/Hematology 2023; 192: 104191 doi: 10.1016/j.critrevonc.2023.104191
|
| 36 |
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. The Oncologist 2023; 28(1): 72 doi: 10.1093/oncolo/oyac186
|
| 37 |
Yonela Ntamo, Khanyisani Ziqubu, Nireshni Chellan, Bongani B. Nkambule, Tawanda M. Nyambuya, Sithandiwe E. Mazibuko-Mbeje, Kwazikwakhe B. Gabuza, Fabio Marcheggiani, Luca Tiano, Phiwayinkosi V. Dludla, Daniela Giustarini. Drug‐Induced Liver Injury: Clinical Evidence of N‐Acetyl Cysteine Protective Effects. Oxidative Medicine and Cellular Longevity 2021; 2021(1) doi: 10.1155/2021/3320325
|
| 38 |
Fernando Bessone, Einar Stefan Bjornsson. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World Journal of Hepatology 2022; 14(7): 1269-1276 doi: 10.4254/wjh.v14.i7.1269
|
| 39 |
Ruben De Wilde, Michael Saerens, Anne Hoorens, Anja Geerts, Celine Jacobs. Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature. International Journal of Translational Medicine 2023; 3(3): 274 doi: 10.3390/ijtm3030019
|
| 40 |
Casey Fazer-Posorske, Lisa Kottschade, Anna Schwecke. The Basics of Cancer Immunotherapy. 2024; : 179 doi: 10.1007/978-3-031-59475-5_14
|
| 41 |
Lorenza Di Marco, Adriana Romanzi, Alessandra Pivetti, Nicola De Maria, Federico Ravaioli, Massimiliano Salati, Erica Villa, Fabrizio Di Benedetto, Paolo Magistri, Massimo Dominici, Antonio Colecchia, Stefano Di Sandro, Andrea Spallanzani. Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation. Critical Reviews in Oncology/Hematology 2025; 207: 104607 doi: 10.1016/j.critrevonc.2024.104607
|
| 42 |
Huan Zhang, Yutong Pang, Ling Yi, Xiaojue Wang, Panjian Wei, Haichao Wang, Shuye Lin. Epigenetic regulators combined with tumour immunotherapy: current status and perspectives. Clinical Epigenetics 2025; 17(1) doi: 10.1186/s13148-025-01856-6
|
| 43 |
Hui Yang, Haozhou Wang, Xiaoguang Zhou, Xiaodong Zhang. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. Clinical Therapeutics 2023; 45(2): 151 doi: 10.1016/j.clinthera.2023.01.001
|
| 44 |
Connor Frey. Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database. Pharmacoepidemiology 2024; 4(1): 1 doi: 10.3390/pharma4010001
|
| 45 |
Bitao Wang, Shaowei Zhuang, Shengnan Lin, Jierong Lin, Wanxian Zeng, Bin Du, Jing Yang. Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data. Hepatology International 2025; doi: 10.1007/s12072-025-10783-w
|
| 46 |
Gres Karim, Megha Reddy, Navim Mobin, Ilan Weisberg, Amreen Dinani. Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clinical Liver Disease 2024; 23(1) doi: 10.1097/CLD.0000000000000096
|
| 47 |
Rolf Teschke. Treatment of Drug-Induced Liver Injury. Biomedicines 2022; 11(1): 15 doi: 10.3390/biomedicines11010015
|
| 48 |
Yujie Wang, Wen Xie. Drug-induced liver injury: An overview and update. Gastroenterology & Endoscopy 2023; 1(2): 102 doi: 10.1016/j.gande.2022.11.005
|
| 49 |
Rolf Teschke, Gaby Danan. Idiosyncratic DILI and RUCAM under One Hat: The Global View. Livers 2023; 3(3): 397 doi: 10.3390/livers3030030
|
| 50 |
Soo Young Hwang, Pinghsin Hsieh, Wei Zhang. Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis. Hepatology Communications 2024; 8(10) doi: 10.1097/HC9.0000000000000525
|
| 51 |
Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo. Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver. International Journal of Molecular Sciences 2024; 25(21): 11676 doi: 10.3390/ijms252111676
|
| 52 |
Alexander Coukos, Julien Vionnet, Michel Obeid, Hasna Bouchaab, Solange Peters, Sofiya Latifyan, Alexandre Wicky, Olivier Michielin, Haithem Chtioui, Darius Moradpour, François Fasquelle, Christine Sempoux, Montserrat Fraga. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 2022; 10(10): e005635 doi: 10.1136/jitc-2022-005635
|
| 53 |
Robyn Laube, Ken Liu. Microbiome in Gastrointestinal Cancer. 2023; : 163 doi: 10.1007/978-981-19-4492-5_11
|
| 54 |
Kelly Torosian, Shravan Dave. Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?. Alimentary Pharmacology & Therapeutics 2024; 60(11-12): 1621 doi: 10.1111/apt.18308
|
| 55 |
Pengfei Zhao, Lihong Yu, Wenming Ma, Ting Zhao. Clinical Manifestations and Risk Factors of Liver Injury Induced by PD-1 Inhibitors in Patients with Malignancies: A Case-Control Study. Therapeutics and Clinical Risk Management 2025; : 309 doi: 10.2147/TCRM.S510973
|
| 56 |
S Kang, HJ Lee, HJ Lee. Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma. Journal of Postgraduate Medicine 2023; 69(3): 172 doi: 10.4103/jpgm.jpgm_834_22
|
| 57 |
Hongye Yang, Mingzhu Lin, Mengxing Liu, Huawei Gu, Dan Li, Yu Shi, Xidong Hou. Evaluate the value of prolonging the duration of tiopronin for injection administration in preventing hepatotoxicity. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54314-3
|
| 58 |
Rebecca Jeun, Priyanka C Iyer, Conor Best, Victor Lavis, Jeena M Varghese, Sireesha Yedururi, Veronica Brady, Isabella C Glitza Oliva, Ramona Dadu, Denai R Milton, Kristy Brock, Sonali Thosani. Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center. Immunotherapy 2023; 15(6): 417 doi: 10.2217/imt-2021-0316
|
| 59 |
Bo Yang, Wei Gou, Naiying Lan, Qing Shao, Weifeng Hu, Cheng Xue, Nanmei Liu. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1347896
|
| 60 |
Stephanie L. Gu, Sandy Nath, Alina Markova. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events. Pharmaceuticals 2023; 16(11): 1610 doi: 10.3390/ph16111610
|
| 61 |
Linnea Swanson, Ihab Kassab, Irene Tsung, Francis P Worden, Robert J Fontana. Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma. Immunotherapy 2022; 14(6): 409 doi: 10.2217/imt-2021-0191
|
| 62 |
Yi Luo, Fei Teng, Hong Fu, Guo-Shan Ding. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World Journal of Gastrointestinal Oncology 2022; 14(1): 163-180 doi: 10.4251/wjgo.v14.i1.163
|
| 63 |
Monica Shahid, Sean Davis, Geoffrey Peters, Daphne Loh, Jonathan McGuane, James Fergusson. Hepatic resection for metastatic melanoma in the era of targeted therapy: A case report. International Journal of Surgery Case Reports 2024; 121: 110033 doi: 10.1016/j.ijscr.2024.110033
|
| 64 |
Adriana M. Kahn, Kim R.M. Blenman, Steve T. Sonis, Maryam B. Lustberg. Strategies to Mitigate the Toxicity of Cancer Therapeutics. Advances in Cancer Research 2022; 155: 215 doi: 10.1016/bs.acr.2022.02.006
|
| 65 |
Andrew Kynaston, Ken Liu, Alex Davis, Steven Kao, Catriona McKenzie. A case of steroid responsive nivolumab induced cholangitis. Pathology 2022; 54(6): 820 doi: 10.1016/j.pathol.2021.11.009
|
| 66 |
Dongxuan Li, Jie Dong, Xin Xi, Guili Huang, Wenjun Li, Cheng Chen, Jun Liu, Qian Du, Songqing Liu. Impact of pharmacist active consultation on clinical outcomes and quality of medical care in drug-induced liver injury inpatients in general hospital wards: A retrospective cohort study. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.972800
|
| 67 |
Tomomi Hamaguchi, Makoto Ueno, Satoshi Kobayashi, Shun Tezuka, Manabu Morimoto, Terufumi Kato, Haruhiro Saito, Shinya Sato, Junji Furuse, Shin Maeda. Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report. Case Reports in Gastroenterology 2024; 19(1): 14 doi: 10.1159/000542598
|
| 68 |
Alberto Savino, Alberto Rossi, Stefano Fagiuoli, Pietro Invernizzi, Alessio Gerussi, Mauro Viganò. Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. Cancers 2024; 17(1): 76 doi: 10.3390/cancers17010076
|
| 69 |
Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao, Hanping Wang. Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database. Cancer Immunology, Immunotherapy 2024; 74(1) doi: 10.1007/s00262-024-03858-4
|
| 70 |
Lukas S. Baumert, Angela R. Shih, Raymond T. Chung. HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition. Med 2024; 5(2): 126 doi: 10.1016/j.medj.2024.01.002
|
| 71 |
Skaistė Astašauskaitė, Rita Kupčinskaitė-Noreikienė, Inga Zaborienė, Rūta Vaičiūnienė, Tomas Vanagas, Darius Pranys, Lina Poškienė, Elona Juozaitytė. Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case Report. Medicina 2024; 60(7): 1129 doi: 10.3390/medicina60071129
|
| 72 |
Na Li, Yong Feng, XiaoLing Chen, Ye Li, Chengmiao Zhang, Yin Yin. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1213608
|